Integra Lifesciences Holdings (IART) Non Operating Interest Expenses (2009 - 2026)

Integra Lifesciences Holdings has disclosed Non Operating Interest Expenses across 18 years of filings, most recently posting $23.0 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 9.28% year-over-year to $23.0 million; the TTM figure through Jun 2026 stood at $91.9 million (up 17.44% YoY), while the FY2025 annual figure was $86.3 million, up 22.12% from the prior year.
• Non Operating Interest Expenses came in at $23.0 million for Q2 2026 at Integra Lifesciences Holdings, up from $22.5 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $23.7 million in Q4 2025 to a low of $11.7 million in Q1 2022.
• Average Non Operating Interest Expenses over 5 years is $16.9 million, with a median of $16.2 million recorded in 2023.
• Year-over-year, Non Operating Interest Expenses dropped 9.85% in 2022 and surged 49.64% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $12.9 million in 2022, then advanced by 6.65% to $13.8 million in 2023, then surged by 38.06% to $19.0 million in 2024, then advanced by 24.7% to $23.7 million in 2025, then retreated by 2.87% to $23.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $23.0 million in Q2 2026, $22.5 million in Q1 2026, and $23.7 million in Q4 2025.